High materiality8/10
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
Why it may matterVerify against the original reporting
Strong upside potential remains (~93% from current price) despite the downgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Roth Capital lowers PMN target to $29 from $30; posted price $15.15; price down 2.08% since signal.
- Target $29; price $15.15; -2.08% since signal.
Key facts
- 01
Target: $29
- 02
Posted price: $15.15
- 03
Analyst firm: Roth Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.